DoD Psychedelic Treatment Research Clinical Trial Award
ID: 355725Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Others

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355725
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Fiscal Year 2024 Psychedelic Treatment Research Clinical Trial Award (PTRCTA) to support clinical trials evaluating treatments for post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI) using covered psychedelic substances. Applicants must focus on at least one of the specified conditions and select from a list of approved psychedelics, with the goal of conducting trials that assess safety and efficacy outcomes among active-duty Service Members. This initiative, with an estimated total funding of $9.8 million, aims to foster collaborations across military, academic, and federal institutions, ensuring that the proposed studies benefit Service Members while addressing women's health considerations. Interested parties should submit their applications by October 4, 2024, and can reach the CDMRP Help Desk at help@eBRAP.org for further inquiries.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524DMRDPPTRCTA_GG.pdf
    The Department of Defense is announcing funding opportunities through the Defense Medical Research and Development Program for clinical trials involving psychedelic treatments for post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI) with a total budget of $10 million. The pre-application deadline is September 20, 2024, while full applications must be submitted by October 4, 2024, focusing on the recruitment of active-duty service members and ensuring collaboration across military, academic, and federal institutions. Applications must include specific research parameters, detailed clinical protocols, and a comprehensive strategy for data management, ethical considerations, and regulatory compliance.
    Similar Opportunities
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Airman Readiness Medical Research (ARMR) Hybrid BAA
    Air Force -- Research Lab
    The Air Force Research Laboratory (AFRL) is soliciting proposals for the Airman Readiness Medical Research (ARMR) program through a Hybrid Broad Agency Announcement (BAA) designated FA8650-20-S-6008. The primary objectives of this initiative are to conduct medical research aimed at optimizing the health and performance of Airmen, focusing on ensuring medical availability and understanding the effects of various operational environments on Airman well-being. This program is critical for enhancing the operational readiness of military personnel, particularly in high-demand mission scenarios, with key research areas including aeromedical evacuation, cognitive performance, and exposure health. The total funding available for this program is estimated at $480 million, with individual awards ranging from $50,000 to $49 million. Interested parties are encouraged to submit white papers by May 1, 2025, and can direct inquiries to Amber A. Taylor at amber.taylor.9@us.af.mil.
    NFRP Outreach and Invitation for Response
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is forecasting an opportunity for a Research-based Other Transactions Agreement (rOTA) under the Neurofibromatosis Research Program (NFRP). This initiative aims to accelerate the clinical translation of basic research related to neurofibromatosis (NF) by conducting collaborative Phase I and II clinical trials focused on promising therapeutic agents for NF1, NF2, and schwannomatosis. Historically, this requirement has been addressed through assistance agreements, and the government is now seeking feedback on this proposed approach, emphasizing the need for cost-sharing arrangements and access to patient populations. Interested parties can direct inquiries to Jason D. Kuhns at jason.d.kuhns.civ@mail.mil, with the opportunity being part of the FY21 portfolio and requiring a demonstrated history of collaborative research among participants.
    UNITED STATES ARMY RESEARCH INSTITUTE FOR THE BEHAVIORAL AND SOCIAL SCIENCES (ARI) BROAD AGENCY ANNOUNCEMENT FOR BASIC, APPLIED, AND ADVANCED SCIENTIFIC RESEARCH
    Dept of the Army -- Materiel Command
    The Department of the Army, through the United States Army Research Institute for the Behavioral and Social Sciences (ARI), has issued a Broad Agency Announcement (BAA) for Basic, Applied, and Advanced Scientific Research, effective from May 1, 2023, to April 30, 2028. This initiative aims to solicit proposals for research and development in areas such as personnel assessment, leadership development, team dynamics, and technology fluency, with a focus on enhancing Army readiness and performance through innovative approaches to talent management. Eligible applicants include institutions of higher education, non-profit organizations, and for-profit entities, while government entities are excluded from prime contracts. Interested parties should submit white papers to streamline the proposal process, with a total of approximately 1,000 awards expected. For further inquiries, applicants can contact Wilveria A. Sanders at wilveria.a.sanders.civ@army.mil, and proposals must be submitted by April 30, 2028.
    Tactical Behaviors for Autonomous Maneuver
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Department of Army Energetics Basic Research Center (EBRC) Fiscal Year 2025
    Dept of the Army -- Materiel Command
    The Department of the Army, through the Materiel Command, is offering a funding opportunity for the Energetics Basic Research Center (EBRC) for Fiscal Year 2025, aimed at advancing research in energetic materials (EM) critical to U.S. national security. This initiative invites eligible applicants, including universities, nonprofit organizations, state and local governments, and for-profit entities, to submit white papers and proposals that focus on innovative research in EMs, particularly in areas such as novel materials, microstructure influence, and advanced diagnostics. The program is designed to enhance the Army's capabilities in developing new materials and technologies that improve weapon systems' performance and effectiveness, with a total funding ceiling of $1 million anticipated for up to six awards ranging from $60,000 to $250,000 per year. Interested parties should submit white papers by January 6, 2025, and proposals by invitation by April 7, 2025; for further inquiries, contact Schon Zwakman at schon.m.zwakman.civ@army.mil or by phone at 919-541-4722.
    Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: NIH-DOD-VA Pain Management Collaboratory � Pragmatic and/or Implementation Science Demonstration Projects ((UG3/UH3) Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the HEAL Initiative, specifically targeting the NIH-DOD-VA Pain Management Collaboratory to support pragmatic and implementation science demonstration projects. This initiative aims to conduct large-scale clinical trials focusing on nonopioid pain management strategies and addressing opioid misuse among U.S. Veterans, military personnel, and their families. The funding opportunity, which will be structured as a cooperative agreement, is expected to provide approximately $850,000 for one award, with the NOFO anticipated to be published in Fall 2024 and applications due by November 2024. Interested applicants should prepare to develop collaborative projects that align with the goals of the Pain Management Collaboratory, with an estimated award date set for July 1, 2025.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "HEAL Initiative: Translating Research to Practice to End the Overdose Crisis" (RFA-DA-25-078), aimed at supporting research that transforms addiction treatment and care to combat the ongoing overdose crisis. This initiative encourages phased applications (R61/R33), where the R61 phase focuses on exploratory activities without the need for existing pilot data, while the R33 phase seeks to implement larger studies based on successful R61 milestones, emphasizing stigma-free and patient-centered approaches. With up to $10 million allocated for FY2026 and a maximum award period of six years, applicants must include a Plan for Enhancing Diverse Perspectives (PEDP) to ensure inclusivity, and applications are to be submitted through Grants.gov by the closing date of March 20, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.